09:21 AM EST - Oncolytics Biotech Inc : Today announced recent operational highlights and financial results for the third quarter ended September 30, 2022. Operational highlights include; Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate nearly triple the average ORR seen in relevant historical control trials. $32.4 million in cash and cash equivalents as of September 30, 2022 provides projected runway through key milestones to the end of 2023. Oncolytics Biotech Inc
shares T.ONC are trading -$0.03 at $1.70.
